TransQST aims to develop novel computational approaches using the best available data from the public and private domains to improve the understanding of adverse drug reactions (i.e. unwanted side effects of medication) in order to reduce significantly patient morbidity, mortality and hospitalisation costs.

The TrasnQST project has an initial budget of €16M distributed across 21 partner (8 pharmaceutical companies, 3 Small and Medium-sized enterprises (SMEs) and 10 academic institutions), sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU).

For more information, contact info@transqst.org or check out www.transqst.org

Related Entries